Results Announced From Phase 3 Studies of Ofatumumab in Relapsing National Multiple Sclerosis Society
August 30, 2019
August 30, 2019
NEW YORK, Aug. 30 -- The National Multiple Sclerosis Society issued the following news:
* * *
- Top-line results were announced from two Phase 3 studies comparing ofatumumab (Novartis) to oral Aubagio(R) (teriflunomide, Sanofi Genzyme) in people with relapsing MS. Ofatumumab is self-administered as a monthly under-the-skin injection.
- According to a company press release, the studies met their primary and key secondary endpoints, significantly reducing the . . .
* * *
- Top-line results were announced from two Phase 3 studies comparing ofatumumab (Novartis) to oral Aubagio(R) (teriflunomide, Sanofi Genzyme) in people with relapsing MS. Ofatumumab is self-administered as a monthly under-the-skin injection.
- According to a company press release, the studies met their primary and key secondary endpoints, significantly reducing the . . .